Seminars in Oncology
Volume 33 , Pages 11-16 , February 2006

Clinical Experience With Denileukin Diftitox (ONTAK)

  • Francine Foss

      Affiliations

    • Corresponding Author InformationAddress correspondence and reprint requests to Francine Foss, MD, Hematologic Malignancies, Medical Oncology, Yale Cancer Center, 333 Cedar St, New Haven, CT 06520

References 

  1. Kim YH , Hoppe RT . Mycosis fungoides and the Sezary syndrome . Semin Oncol . 1999;26:276–289
  2. http://www.cancer.gov/cancertopics/pdq/treatment/mycosisfungoides/patient (Accessed June 13, 2005)
  3. Jones GW , Rosenthal D , Wilson LD . Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sezary syndrome) . Cancer . 1999;85:1985–1995
  4. Weidmann E , Sacchi M , Plaisance S , et al.   Receptors for interleukin 2 on human squamous cell carcinoma cell lines and tumor in situ . Cancer Res . 1992;52:5963–5970
  5. LeMaistre CF . DAB(389)IL-2 (denileukin diftitox, ONTAK) (Other potential applications) . Clin Lymphoma . 2000;1:S37–S40 (suppl 1)
  6. LeMaistre CF , Saleh MN , Kuzel TM , et al.   Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2 . Blood . 1998;91:399–405
  7. Foss FM . DAB(389)IL-2 (ONTAK) (A novel fusion toxin therapy for lymphoma) . Clin Lymphoma . 2000;1:110–117
  8. Bacha P , Williams DP , Waters C , et al.   Interleukin 2 receptor-targeted cytotoxicity (Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein) . J Exp Med . 1988;167:612–622
  9. Foss FM . DAB(389)IL-2 (denileukin diftitox, ONTAK) (A new fusion protein technology) . Clin Lymphoma . 2000;1:S27–S31 (suppl 1)
  10. Nakase K , Kita K , Nasu K , et al.   Differential expression of interleukin-2 receptors (alpha and beta chain) in mature lymphoid neoplasms . Am J Hematol . 1994;46:179–183
  11. Re GG , Waters C , Poisson L , et al.   Interleukin 2 (IL-2) receptor expression and sensitivity to diphtheria fusion toxin DAB389IL-2 in cultured hematopoietic cells . Cancer Res . 1996;56:2590–2595
  12. Olsen E , Duvic M , Frankel A , et al.   Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma . J Clin Oncol . 2001;19:376–388
  13. Foss FM , Bacha P , Osann KE , et al.   Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma (Decreased frequency and severity with steroid premedication) . Clin Lymphoma . 2001;1:298–302
  14. Dang NH , Hagemeister FB , Pro B , et al.   Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin’s lymphoma . J Clin Oncol . 2004;22:4095–4102
  15. Ho VT , Zahrieh D , Hochberg E , et al.   Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation . Blood . 2004;104:1224–1226

 This supplement was supported by an unrestricted educational grant from Zeneus Pharma Ltd.

 Prof Foss is a member of the speakers’ bureau for Ligand Pharmaceuticals.

PII: S0093-7754(05)00511-7

doi: 10.1053/j.seminoncol.2005.12.017

Seminars in Oncology
Volume 33 , Pages 11-16 , February 2006

Article Tools

* Image Usage & Resolution